---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-276377"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:46:00.429008+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kymera Q3 2022 net loss $43M, cash $596M; board adds Sandor as Nicholson resigns

## Summary
- Q3 2022 net loss $43.0M ($0.81/sh) vs $28.6M in Q3 2021; collaboration revenue $9.6M vs $20.3M.
- Cash, equivalents & investments $595.6M as of Sep 30, 2022; includes $150M Aug 2022 private placement.
- KT-474 (IRAK4 degrader) patient cohort dosing complete; data to Sanofi in Q4, clinical update Dec 14, 2022.
- Director Don Nicholson resigned Nov 3, 2022 (no disagreement); Victor Sandor appointed to Board same day.
- KT-333 (STAT3 degrader) granted second orphan drug designation (CTCL); KT-253 IND on track for Q4 2022.

## SEC filing metadata
- accession: 0001193125-22-276377
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312522276377/0001193125-22-276377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312522276377/d402248d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-276377
- JSON: https://secwatch.observer/filing/0001193125-22-276377.json
- Plain text: https://secwatch.observer/filing/0001193125-22-276377.txt

## Key facts
- Earnings Releases
  Kymera Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Kymera Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312522276377/0001193125-22-276377-index.htm
- Executive change
  Victor Sandor was appointed as Director at Kymera Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 1, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Victor Sandor, M.D. to join the Board, effective as of November 3, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312522276377/0001193125-22-276377-index.htm
- Executive change
  Donald Nicholson resigned as Director at Kymera Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 31, 2022, Donald Nicholson, Ph.D., a member of the Board of Directors (the “Board”) of the Company and the Compensation Committee of the Board, notified the Company of his resignation from the Board and all committees thereof, effective November 3, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312522276377/0001193125-22-276377-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.